You are here: Industry Insights > Roche

News List

Roche and UCB partner to develop antibody therapy for Alzheimer’s pharmaceutical-technology
July 31, 2020
Roche and its unit Genentech have agreed to a global, exclusive licence agreement with Belgian company UCB to develop and commercialise an antibody treatment, UCB0107, for Alzheimer’s disease.
Roche’s Phase III Trial of Actemra in COVID-19 Misses Primary Endpoint contractpharma
July 31, 2020
COVACTA trial did not meet primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoints.
Actemra/RoActemra, arthritis drug from Roche fails to meet primary endpoint of COVID-19 trial expresspharma
July 30, 2020
The COVACTA study did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe COVID-19 associated pneumonia or identify any new safety signals for Actemra/RoActemra.
Roche, Jnana sign multi-target collaboration deal for small molecule drugs pharmaceutical-business-review
July 24, 2020
Jnana Therapeutics has signed a multi-target collaboration and license deal worth over $1bn with Roche for the discovery of small molecule drugs for the treatment of immune-mediated and neurological diseases.
Roche partners with Jnana on SLC transporters pharmatimes
July 23, 2020
Roche and Jnana Therapeutics have entered into a collaboration to discover new medicines targeting key regulators of cellular metabolism to treat immune-mediated and neurological diseases.
Tecentriq misses mark in ovarian cancer trial pharmatimes
July 15, 2020
Roche and Genentech's Tecentriq (atezolizumab) has failed to hit its primary goal in a late stage trial involving patients with newly diagnosed advanced stage ovarian cancer.
Roche signs up to $1.7bn cancer drug deal with Blueprint Medicines pharmaceutical-technolog
July 15, 2020
Roche has entered into a licensing and collaboration agreement with Blueprint Medicines for exclusive rights to co-develop and commercialise the latter’s cancer drug, pralsetinib, outside the US, except in Greater China.
Roche’s breast cancer drug Phesgo secures US regulatory approval pharmaceutical-technology
July 01, 2020
Roche has received approval from the US Food and Drug Administration (FDA) for Phesgo, in combination with intravenous (IV) chemotherapy, to treat early and metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
US nod for Roche's breast cancer combo pharmatimes
June 30, 2020
US regulators have approved Roche's Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, for the treatment of early and metastatic HER2-positive breast cancer.
Roche not yet meeting demand for molecular COVID-19 tests, chairman says expresspharma
June 30, 2020
Demand for its antibody tests, which determine whether people have ever been infected with the coronavirus, can be met as Roche has been boosting production, he said.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page